Clinical Trial Update: Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II neoadjuvant trial evaluating Sacituzumab Tirumotecan in combination with Osimertinib or Sacituzumab Tirumotecan alone for resectable EGFR-mutated non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING